Expertise in
1
conditions

Isabelle Baumgaertner

Paris, FR 
Expertise in
1
conditions
Paris, FR 

Overview

Isabelle Baumgaertner practices practicing medicine in Paris, France.

Ms. Baumgaertner is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Dihydropyrimidine Dehydrogenase Deficiency, Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Turcot Syndrome.

She is actively involved in clinical research, co-authoring 19 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Paris, France
Other Locations
Creteil, France
Angers, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Drug
Study Drug: Trifluridine/Tipiracil
Study Phase: Phase 2
A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Plus FOLFIRI, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM-D17-01 PRODIGE 63 Study)
A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Plus FOLFIRI, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM-D17-01 PRODIGE 63 Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: FOLFIRI, OSE2101, Nivolumab
Study Phase: Phase 2
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Enrollment Status: Unknown
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: Ramucirumab, Paclitaxel
Study Phase: Phase 2
A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/Capecitabine
A Phase II Study Evaluating the Rate of Cardiovascular Events During Trifluridine/Tipiracil +/- Oxaliplatin Treatment in Colorectal/Oesogastric Adenocarcinoma Patients That Have Experienced a Past Episode of Thoracic Angina-related Pain Due to Chemotherapy Including 5-fluorouracil/Capecitabine
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Drugs: Trifluridine/Tipiracil, Oxaliplatin
Study Phase: Phase 2
The Medical-financial Evaluation of Pre-therapeutic Screening by a Joint Phenotypic-pharmacogenetic Approach for Metabolic Fluoropyrimidine Enzyme Deficiency in Terms of Serious Toxicity Risk Prevention : a Multicentric Case Study
The Medical-financial Evaluation of Pre-therapeutic Screening by a Joint Phenotypic-pharmacogenetic Approach for Metabolic Fluoropyrimidine Enzyme Deficiency in Terms of Serious Toxicity Risk Prevention : a Multicentric Case Study
Enrollment Status: Terminated
Publish Date: March 25, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
View 4 Less Clinical Trials

19 Total Publications

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.
Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 08, 2023

Frequently Asked Questions about Isabelle Baumgaertner

Is Isabelle Baumgaertner a top-rated expert for Dihydropyrimidine Dehydrogenase Deficiency?

MediFind is an objective health platform that identifies experts based on real-world data. Isabelle Baumgaertner is classified as an Advanced expert for Dihydropyrimidine Dehydrogenase Deficiency, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Isabelle Baumgaertner participate in research or clinical trials?

Yes. Isabelle Baumgaertner has published 19 articles and abstracts on conditions like Dihydropyrimidine Dehydrogenase Deficiency. You can view a list of Isabelle Baumgaertner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Baumgaertner's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile